Comment · Sun, March 24, 2013 · Ceretropic
A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.
What they were answering
Direct reply to the original post in this thread.
u/MisterYouAreSoDumb · Ceretropic
>Atomoxetine was also
efficacious, providing evidence that the study was well executed
and sensitive for detecting improvements in ADHD
symptoms. The response to ABT-894 4mg BID was comparable
to that of atomoxetine on the primary analysis of
CAARS:Inv and on all other ADHD efficacy measures. These
results build on the body of literature demonstrating the
ability of NNR agonists to improve attention (Levin et al,
2006). The positive result provides additional support for
the notion that specific agonists of the a4b2 receptor
subtype may be an attractive target for ADHD because of
the anatomical location within the brain, resulting in
improved attention with an acceptable safety and tolerability
profile.